Case management of the anemic patient: epoetin alfa--focus on iron supplementation.
Epoetin alfa stimulates erythropoiesis, thus creating an increased need for iron, and virtually all patients with end-stage renal disease who receive this therapy will eventually require iron supplementation. This article describes the appropriate use of oral and intravenous iron supplementation, including patient assessment, education, and management.
Kirlin
L F
LF
D000368:Aged; D000747:Anemia, Hypochromic / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications*; D010349:Patient Compliance; D010353:Patient Education as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron